Inrig Jula

SEC source: 0001902368-26-000008 · form4-09182026_010947.xml · derivative · entry 6

Inrig Jula · CIK 0001902368 · EVP, Head of R&D & CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,605

Underlying: Common Stock · 32,395 shares

Expires 2034-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001902368-26-000008 · form4-09182026_010947.xml · nonDerivative · entry 5

Inrig Jula · CIK 0001902368 · EVP, Head of R&D & CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,491

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

SEC source: 0001902368-26-000008 · form4-09182026_010947.xml · nonDerivative · entry 4

Inrig Jula · CIK 0001902368 · EVP, Head of R&D & CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,891

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F4 · price: The weighted average sale price for the transaction reported was $63.685, and the range of prices were between $63.58 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001902368-26-000008 · form4-09182026_010947.xml · nonDerivative · entry 3

Inrig Jula · CIK 0001902368 · EVP, Head of R&D & CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,491

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F3 · price: The weighted average sale price for the transaction reported was $62.6242, and the range of prices were between $62.40 and $63.365. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001902368-26-000008 · form4-09182026_010947.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · EVP, Head of R&D & CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,775

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2 · price: The weighted average sale price for the transaction reported was $62.0167, and the range of prices were between $61.40 and $62.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001902368-26-000008 · form4-09182026_010947.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · EVP, Head of R&D & CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001902368-26-000007 · form4-06222026_080607.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,770

F1 · kind: This transaction represents a bona fide gift of 468 shares of common stock to a donor-advised fund. The reporting person authorized the gift on June 16, 2026, and the transfer occurred on June 22, 2026.

SEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 5

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,238

F4 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 4

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,549

F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001902368-26-000006 · form4-05062026_080509.xml · derivative · entry 8

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,250

Underlying: Common Stock · 4,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F2 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F2 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

SEC source: 0001902368-26-000006 · form4-05062026_080509.xml · derivative · entry 7

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

F6 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F2 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F2 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

SEC source: 0001902368-26-000006 · form4-05062026_080509.xml · derivative · entry 6

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,500

Underlying: Common Stock · 20,000 shares

Expires 2033-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and become exercisable on January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 3

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,723

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

SEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,473

F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

SEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,473

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001902368-26-000005 · form4-04162026_010435.xml · nonDerivative · entry 3

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,473

F3 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001902368-26-000005 · form4-04162026_010435.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,491

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001902368-26-000005 · form4-04162026_010435.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,706

F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

SEC source: 0001902368-26-000004 · form4-02052026_040203.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,706

F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The weighted average sale price for the transaction reported was $32.85, and the range of prices were between $32.80 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001902368-26-000004 · form4-02052026_040203.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,938

F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $32.11, and the range of prices were between $31.65 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001902368-26-000003 · form4-02032026_090210.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,485

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001902368-26-000003 · form4-02032026_090210.xml · derivative · entry 3

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2036-01-31

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001902368-26-000003 · form4-02032026_090210.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,441

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001902368-26-000002 · form4-01072026_040106.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,311

F2 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001902368-26-000002 · form4-01072026_040106.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,756

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001902368-25-000005 · form4-12302025_021222.xml · derivative · entry 3

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,000

Underlying: Common Stock · 15,000 shares

Expires 2034-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001902368-25-000005 · form4-12302025_021222.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,787

F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2 · price: The weighted average sale price for the transaction reported was $42.0003, and the range of prices were between $42.00 and $42.015. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001902368-25-000005 · form4-12302025_021222.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,787

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-019108 · form4-07022025_090753.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,787

F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in February 2025.

SEC source: 0001415889-25-003819 · form4-02132025_020211.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,602

F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-25-003819 · form4-02132025_020211.xml · derivative · entry 3

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.

F2 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F2 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

SEC source: 0001415889-25-003819 · form4-02132025_020211.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.

F2 · price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

SEC source: 0001415889-25-003064 · form4-02042025_080213.xml · nonDerivative · entry 3

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,170

F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001415889-25-003064 · form4-02042025_080213.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,236

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-25-003064 · form4-02042025_080213.xml · derivative · entry 4

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2035-01-31

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-003064 · form4-02042025_080213.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,443

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001415889-25-000899 · form4-01072025_120158.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,443

F2 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001415889-25-000899 · form4-01072025_120158.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,883

F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-023128 · form4-09102024_040901.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,949

F1 · kind: This sale was made pursuant to a written plan adopted March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that vested on September 5, 2024.

SEC source: 0001415889-24-023093 · form4-09092024_090907.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,633

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-023093 · form4-09092024_090907.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,824

F1 · kind: On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.

SEC source: 0001415889-24-002281 · form4-02022024_040208.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,074

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-002281 · form4-02022024_040208.xml · derivative · entry 3

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,000

Underlying: Common Stock · 91,000 shares

Expires 2034-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-002281 · form4-02022024_040208.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,248

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001209191-24-001005 · doc4.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,248

F2 · kind: This sale was made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-24-001005 · doc4.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,688

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-23-006420 · doc4.xml · derivative · entry 3

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F3 · derivative.exercise_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

F3 · derivative.expiration_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

SEC source: 0001209191-23-006420 · doc4.xml · derivative · entry 2

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,500

Underlying: Common Stock · 54,500 shares

Expires 2033-01-30

F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-006420 · doc4.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,757

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001209191-23-002325 · doc4.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,507

F2 · kind: This sale was made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.